비인강암 환자의 고선량 강내 방사선 치료의 효과

• 영문명: The Role of High Dose Rate (HDR) Intracavitary Radiation Therapy for the Management of Nasopharyngeal Carcinoma
• 발행기관: 대한방사선종양학회
• 저자명: 조정길 (Jeong Gill Cho) 장혜숙 (Hye Sook Chang) 최은경 (Eun Kyung Choi)
• 간행물 정보: 『대한방사선종양학회지』제11권 제1호, 91~96쪽, 전체 6쪽
• 주제분류: 의약학 > 종양학
• 파일형태: PDF
• 발행일자: 1993.06.30

영문 초록

From September 1989 to June 1992, 22 patients with nasopharyngeal carcinoma were treated in Asan Medical Center with an external beam of 60 Gy followed by a boost dose of 15 Gy HDR brachytherapy. There were 5 females and 17 males with median age of 44 years (range: 20-69 years). All patients were histologically confirmed and staged by physical examination, CT scan and/or MRI. By the AJCC TNM staging system, there were 2 patients with stage II (T2NO), 4 with stage III (T3NO, T1-3N1), and 16 with stage IV (T4 or N2-3). Four patients received chemotherapy with 5-FU and cisplatin prior to radiotherapy. All patients were followed up periodically by a telescopic examination and radiologic imaging study of CT scan or MRI with a median follow-up thime of 13 months (range: 3-34 months). Twenty one patients showed a complete response one month after completing therapy and one patient showed a compete response after three months. At the time of this analysis, seventeen patients remain alive without evidence of disease, but four patients developed distant metastasis and one patient died a month after treatment. the local control rate was 100% in a median follow-up time of 13 months. The two year overall and disease free survival rates by the Kaplan-Meier method were 94% and 67%, respectively. Serious radiation sequelae have not been observed yet. Although longer follow-up in needed, this retrospective analysis suggests that HDR brachytherap. given as a boost therapy for nasoharyngeal carcinoma may improve the local control. To reduce the incidence of distant metastasis, we need to develop a more effective systemic chemotherapy.

목차

abstract

서론

대상 및 방법

결과

고찰

REFERENCES

키워드

Nasopharyngeal carcinoma HER intracavitary radiation therapy.